Successful treatment of BK virus-associated severe hemorrhagic cystitis with bilateral single-J ureteral stenting

Akira Fujita, Kohei Kobatake, Takaumi Fukushima, Kenshiro Takemoto, Syunsuke Miyamoto, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Keisuke Hieda, Shuhei Karakawa, Tetsutaro Hayashi, Jun Teishima and Nobuyuki Hinata

Departments of Urology and Pediatrics, Hiroshima University Hospital, Hiroshima, Japan

Abbreviations & Acronyms
BKV-HC = BK virus-associated hemorrhagic cystitis
CBI = continuous bladder irrigation
CRP = C-reactive protein
Hb = hemoglobin
HC = hemorrhagic cystitis
HSCT = hematopoietic stem cell transplantation
PCy = percutaneous cystostomy
Plt = platelet
PN = percutaneous nephrostomy
RCC = red cell concentrate
TUE = transurethral electrocoagulation

Introduction: BK virus-associated hemorrhagic cystitis is a significant complication of hematopoietic stem cell transplantation. Although severe BK virus-associated hemorrhagic cystitis is associated with treatment-related mortality, sufficient evidence regarding its management is lacking.

Case presentation: A 14-year-old boy presented with BK virus-associated hemorrhagic cystitis and bladder clot retention after hematopoietic stem cell transplantation. Various urological interventions failed to improve cystitis. While bladder clot retention frequently recurred, surgical intervention was difficult because of the underlying hematological disorder. Hence, bilateral single-J ureteral stenting followed by Foley catheter placement was performed as a urinary diversion. The bladder clot completely disappeared 27 days after stenting. No additional procedure was required. BK virus-associated hemorrhagic cystitis did not recur after the blood clot disappeared.

Conclusion: Bilateral single-J ureteral stenting followed by Foley catheter placement is a simple and effective treatment method and should be considered before surgical intervention for severe BK virus-associated hemorrhagic cystitis.

Key words: BK virus, hematopoietic stem cell transplantation, hemorrhagic cystitis, ureteral stent, urinary diversion.

Keynote message
The authors report the first case of BK virus-associated severe hemorrhagic cystitis successfully treated with bilateral single-J ureteral stenting, followed by Foley catheter placement. As the proposed method is simple and effective, it should be considered before surgical intervention for severe BKV-HC.
was postponed due to financial issues. Frequent transfusions of RCC and PCy failed to improve Hb level and Plt count after HSCT (Fig. 1).

The BKV-HC with bladder clot retention persisted for 4 months with temporary improvement and recurrence; hence, frequent manual bladder washout and CBI were performed each time. TUE performed under general anesthesia on days 84 and 117 also failed to improve BKV-HC. The bladder wall was diffusely edematous and hemorrhagic (Fig. 2a). A bilateral 6 Fr single-J stent (Fig. 2b) and 8 Fr Foley catheter were placed using a flexible cystoscope without manual bladder washout on day 120. As a result, the bladder clot gradually decreased, spontaneously drained from the catheter, and completely disappeared 27 days after stenting (Fig. 2c). The patient complained of slight pain in the external urethral meatus but not in the lower abdomen. No additional procedures, including manual bladder washout, were needed. Gross hematuria did not recur after the blood clot disappeared despite Hb level and Plt count remaining low. The bilateral SJ stents were removed 97 days after being placed, followed by the removal of the Foley catheter (Fig. 1). Urine tests showed decreased BK virus levels \((1.0 \times 10^8 \text{ copies/mL})\), at 8 months post-HSCT, BKV-HC has not recurred.

**Discussion**

Therapy for severe HC is stressful for patients because of recurrent clot retention and the necessity for bladder irrigation.³ Our decision to place bilateral single-J ureteral stents was based on the following possible mechanisms: (i) decreased bladder distension by urine, thereby reducing microtrauma; (ii) protection from urinary urokinase, which prevents clot formation; (iii) bladder packing by the clot and subsequent bladder mucosal healing and bleeding cessation.⁴ Foley catheter placement played an important role in maintaining the position of the stent and discharge of fibrinolyzed blood clots. In fact, the bladder did not hyperextend painfully, possibly because of the loss of influx of urine, followed by bladder packing and hemostasis by blood clots.

Urologists do not have sufficient evidence to support the management of severe HC after HSCT. We have summarized retrospective studies and a non-randomized control study on urologic intervention for severe HC after HSCT (Table 1). CBI after the placement of a urinary catheter may be the most common procedure for HC. It significantly reduces the mean duration of HC and hospitalization, with no adverse effects, and also reduces the incidence of late-onset HC.³ However, upon defining a case in which the irrigation line was completely blocked as a failure of CBI, high CRP values (>8.89 ng/mL), low age (<14.5 years), and late-onset time of HC after HSCT (>37 days) were reported to be independent risk factors for failure.¹¹ For urinary diversion with a surgical approach, the most common procedure is bilateral PN, followed by PCy. In patients with bilateral PN, the mortality rate was 55%, similar to the total mortality rate of severe HC.¹² Another report showed that bilateral PN was not associated
with increased mortality, and no deaths were observed that were directly attributed to PN. In patients requiring PCy, the rates of mortality and transfusion requirement were significantly higher than in those who responded to medical therapy. Thus, PCy for severe HC was suggested to be undertaken only after the failure of medical therapy. Cystectomy with urinary diversion, TUE, and laser vaporization as other urinary interventions were reported only in case reports. Some procedures lead to temporary or complete hemostasis; however, cystectomy, carries substantial risk in immunocompromised patients, should be considered a last resort.

To our knowledge, this is the first report of successful treatment of BKV-HC after HSCT using bilateral single-J ureteral stenting. The mechanism of hemostasis is similar to that of PN; therefore, similar effects to PN can be expected without the risk of kidney bleeding. Our method is simple and less invasive; in addition, it does not impair the patients’ activities of daily living compared to the methods in previous reports. This procedure should be attempted before surgical intervention for severe BKV-HC after HSCT in combination with appropriate pain control. The age of the patient is an important consideration for our procedure; at the very least, patients should be old enough to undergo cystoscopy. The risk of developing BK virus-related nephropathy due to the placement of ureteral stents should be considered even though the patients already have BK viruria.

**Conclusion**

Bilateral single-J ureteral stenting followed by Foley catheter placement is a simple and effective method for the treatment of BKV-HC. Hence, it should be considered before surgical interventions.

**Acknowledgments**

We thank Satoshi Shirane, Kenta Fujiyama, Tomoki Furutani, Maiko Shimomura, and Saya Yamane, for their medical

---

**Table 1** Studies of urologic intervention for HC after HSCT

| Author                | Year | Type of study                  | Procedure  | No. of patients | Outcomes                                                                 |
|-----------------------|------|--------------------------------|------------|-----------------|--------------------------------------------------------------------------|
| Hadjibabai et al.     | 2008 | Non-randomized controlled study | CBI        | 40 (CBI) vs 40 (control) | CBI reduced the duration of HC CBI reduced the incidence of late-onset HC |
| Yang et al.           | 2020 | Retrospective study            | CBI        | 227             | Independent risk factors for failure of CBI were higher CRP, lower age, and late onset HC |
| Lukasewycz et al.     | 2012 | Retrospective study            | Bilateral PN | 11 out of 40    | 45% of HC resolved within 30 days. The mortality rate was 55% in PN, same as the total mortality rate of severe HC |
| Au et al.             | 2017 | Retrospective study            | Bilateral PN | 5 out of 43     | PN not associated with increased mortality. No deaths that were directly attributed to PN |
| Baronciani, et al.    | 1995 | Retrospective study            | PCy        | 11 out of 73     | Higher mortality rate than responder of medical therapy |

---

**Fig. 2** Urologic interventions and the change of the bladder blood clot. (a) Images of the bladder wall during TUE with cystoscope on day 84 (upper panel) and day 117 (lower panel) after HSCT. (b) X-ray image taken during bilateral single-J ureteral stent placement. (c) Sagittal section on ultrasonography of the bladder blood clot on days 0, 5, and 27 post-stenting. The long diameter of the clot was reduced from 85 to 71 mm and then to 0 mm.
support. We would also like to thank Editage (www.editage.com) for English language editing.

**Author Contributions**

Akira Fujita: Conceptualization; data curation; visualization; writing – original draft. Kohei Kobatake: Conceptualization; writing – review and editing. Takafumi Fukushima: Investigation. Kenshiro Takemoto: Investigation. Syunsuke Miyamoto: Investigation. Hiroiuki Kitano: Validation. Kenichiro Ikeda: Methodology. Keisuke Goto: Methodology. Jun Teishima: Supervision. Nobuyuki Hinata: Supervision.

**Conflict of interest**
The authors declare no conflict of interest.

**Approval of the research protocol by an Institutional Review Board**
Not applicable.

**Informed consent**
The patient involved provided informed consent for the publication of this study.

**Registry and the Registration No. of the study/trial**
Not applicable.

**References**

1 Mohammadi Najafabadi M, Soleimani M, Ahnadadvand M, Soufi Zomorrod M, Mousavi SA. Treatment protocols for BK virus associated hemorrhagic cystitis after hematopoietic stem cell transplantation. Am. J. Blood Res. 2020; 10: 217–30.

2 Abudayeh A, Hamdi A, Lin H et al. Symptomatic BK virus infection is associated with kidney function decline and poor overall survival in allogeneic hematopoietic stem cell recipients. Am. J. Transplant. 2016; 16: 1492–502.

3 Hadjibabaei M, Alimoghadam K, Shamshiri AR et al. Continuous bladder irrigation prevents hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Urol. Oncol. 2008; 26: 43–6.

4 Aldiwani M, Thazakan T, Al-Hassani A, Gibbons N, Pavlu J, Hroudka D. BK virus associated Haemorrhagic cystitis. A systematic review of current prevention and treatment strategies. Int. J. Surg. 2019; 63: 34–42.

5 Gilis L, Morisset S, Billaud G et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014; 49: 664–70.

6 Sièbe P, Garderet L, Traxer O, Nouri M, Gluckman E, Gatgegno B. Subtotal cystectomy with ileocystoplasty for severe hemorrhagic cystitis after bone marrow transplantation. Urology 2001; 57: 168.

7 Harkensee C, Vasdev N, Gennery AR, Willetts IE, Taylor C. Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation—a systematic review and evidence-based guidance for clinical management. Br. J. Haematol. 2008; 142: 717–31.

8 Vigeli TA, Peinemann F, Burdach S, Ackermann R. Urological treatment and clinical course of BK polyomavirus-associated hemorrhagic cystitis in children after bone marrow transplantation. Eur. Urol. 1999; 36: 252–7.

9 Kurosawa K, Urakami S, Ishiwata K et al. Significance of urological surgical treatment for viral hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Hinyokika Kiyo 2016; 62: 563–7.

10 Cesaro S, Dalianis T, Hanssen Rinaldo C et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J. Antimicrob. Chemother. 2017; 73: 12–21.

11 Yang W, Du Y, Qu Z et al. Multivariate analysis of factors for failed continuous bladder irrigation in hemorrhagic cystitis patients after hematopoietic stem cell transplantation. BMC Urol. 2020; 20: 184.

12 Lukacewycz SJ, Smith AR, Rambachan A, MacMillan ML, Lewis JM, Shukla AR. Intractable hemorrhagic cystitis after hematopoietic stem cell transplantation – is there a role for early urinary diversion in children? J. Urol. 2012; 188: 242–6.

13 Au JK, Graziano C, Elizondo RA et al. Urologic outcomes of children with hemorrhagic cystitis after bone marrow transplant at a single institution. Urology 2017; 101: 126–32.

14 Baronciani D, Angelucci E, Erer B et al. Suprapubic cystotomy as treatment for severe hemorrhagic cystitis after bone marrow transplantation. Bone Marrow Transplant. 1995; 16: 267–70.

15 Garderet L, Bittencourt H, Seibe P et al. Cystectomy for severe hemorrhagic cystitis in allogeneic stem cell transplant recipients. Transplantation 2000; 70: 1807–11.

16 Hashim F, Rehman S, Gregg JA, Dharnidharka VR. Ureteral stent placement increases the risk for developing BK Viremia after kidney transplantation. J. Transplant. 2014; 2014: 459747.

17 Wingate JT, Brandenberger J, Weiss A, Scovel LG, Kuhr CS. Ureteral stent duration and the risk of BK polyomavirus viremia or bacteruria after kidney transplantation. Transpl. Infect. Dis. 2017; 19: e12644.

**Editorial Comment**

**Editorial Comment on Additional approach for BK virus-associated severe hemorrhagic cystitis with bilateral single-J ureteral stenting**

Hematopoietic stem cell transplantation (HSCT) is the most performed cure for patients with certain cancers of the blood or bone marrow, such as leukemia, lymphoma, or multiple myeloma. In these cases, the recipient’s immune system is usually destroyed with radiation or chemotherapy before the transplantation. Infections are one of the most annoying complications during immune deficiency and cause of death after HSCT. About one-third of infection-related deaths are due to viruses such as human adenovirus, Epstein–Barr virus, human cytomegalovirus (CMV), and BK virus. BK virus infection leads to BK virus-associated hemorrhagic cystitis (BKV-HC) which is considered as one of the major...